Cannabis company Canopy Growth Corporation releases fourth quarter results

By gor goz
Share

Canopy Growth Corporation, the Ontario based cannabis company, has announced its financial results for the fourth quarter of FY19.

In the company’s June 20 press release, Canopy Growth highlighted the achievement of annual net revenue growth of 191% to $226.3mn. In the fourth quarter, revenue grew by 13% versus the third quarter, which the company credited to value-added products, extraction services and clinic partners.

Over the 2019 financial year, Canopy Growth said that they shipped 24,300 kilograms and kilogram equivalents of products, including 16,300 kilograms of dry flower and 8,000 kilogram equivalents of oil and softgels. Also detailed was a $5bn investment from Constellation Brands, which is to be used to accelerate the company’s global expansion.

SEE ALSO:

"The fourth quarter wraps up a historic year with major steps taken in Canada to build-out our national platform while scaling all of our processes to bring cannabis to market,” said Bruce Linton, Chairman and Co-CEO of Canopy Growth. “The third quarter of the year benefitted from months of advanced production while the fourth quarter relied more on efficient throughput and a more automated platform. With more product formats coming to the Canadian market later in the year, we are working hard to ensure that we are ready to hit the ground running with products, formats and brands that Canadians trust."

Canopy Growth is the world’s largest cannabis company by market capitalization, and is listed on the TSX under the symbol “WEED” and NYSE under the symbol “CGC”.

Share

Featured Articles

UK Entrepreneurs Ratchet Up Selling Off Their Businesses

British business owners spooked by impending tax hikes accelerate plans to sell off their businesses, as executives of UK-listed companies dump shares

UK Employment Rights Bill - What It Means for Your Business

Government introduces the biggest reform to UK employment law in a generation. Here’s what it means for your business

Q&A: Former Novartis CEO Daniel Vasella - McKinsey

Former Novartis CEO Daniel Vasella talks to McKinsey about how his attitudes to leadership have changed and why he’s not afraid to be vulnerable

Share of Population Who are Millionaires to Drop by 20%

Corporate Finance

Why Are US CEOs Stampeding for the Exit Sign?

Human Capital

Companies Wasting Millions on AI Spending - MIT Professor

Technology & AI